BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22926567)

  • 1. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
    Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
    Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening of compounds library to identify novel inhibitors against latent Mycobacterium tuberculosis using streptomycin-dependent Mycobacterium tuberculosis 18b strain as a model.
    Sharma S; Bhat R; Singh R; Sharma S; Wazir P; Singh PP; Vishwakarma RA; Khan IA
    Tuberculosis (Edinb); 2020 Sep; 124():101958. PubMed ID: 32791471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.
    Vocat A; Hartkoorn RC; Lechartier B; Zhang M; Dhar N; Cole ST; Sala C
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4012-9. PubMed ID: 25896710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium tuberculosis strain 18b, a useful non-virulent streptomycin dependent mutant to study latent tuberculosis as well as for in vivo and in vitro testing of anti-tuberculosis drugs.
    Campos-Neto A
    Tuberculosis (Edinb); 2016 Jul; 99():54-55. PubMed ID: 27450005
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
    Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
    Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
    Reddy VM; Einck L; Andries K; Nacy CA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2840-6. PubMed ID: 20385864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
    Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
    Rullas J; García JI; Beltrán M; Cardona PJ; Cáceres N; García-Bustos JF; Angulo-Barturen I
    Antimicrob Agents Chemother; 2010 May; 54(5):2262-4. PubMed ID: 20160054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
    Xu J; Lu Y; Fu L; Zhu H; Wang B; Mdluli K; Upton AM; Jin H; Zheng M; Zhao W; Li P
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1119-25. PubMed ID: 22691726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
    Alffenaar JW; van der Laan T; Simons S; van der Werf TS; van de Kasteele PJ; de Neeling H; van Soolingen D
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1287-9. PubMed ID: 21199931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.
    Sarathy J; Dartois V; Dick T; Gengenbacher M
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1648-53. PubMed ID: 23335744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
    Karabanovich G; Zemanová J; Smutný T; Székely R; Šarkan M; Centárová I; Vocat A; Pávková I; Čonka P; Němeček J; Stolaříková J; Vejsová M; Vávrová K; Klimešová V; Hrabálek A; Pávek P; Cole ST; Mikušová K; Roh J
    J Med Chem; 2016 Mar; 59(6):2362-80. PubMed ID: 26948407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.